Clinical Trial Update: Follow-up of the VIPES Study to Evaluate Efficacy and Safety of Viaskin Peanut in Adults and Children [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial update for Viaskin Peanut in adults and children with peanut allergy, reporting completed status and posted results in 2022.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Peanut Allergy

Drugs mentioned

• Viaskin Peanut (peanut epicutaneous immunotherapy patch)

Snippet

Sponsor: DBV Technologies | Conditions: Peanut Allergy | Phase 2 | Status: COMPLETED | Results posted: 2022-06-30